NCT06098313View on ClinicalTrials.gov

HCT With PTCy in Higher-risk MDS

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

113

Participants

Timeline

Start Date

July 1, 2020

Primary Completion Date

May 31, 2027

Study Completion Date

May 31, 2027

Conditions
Patients With MDS, Acute Myeloid Leukemia (AML) Evolving From MDS, and Chronic Myelomonocytic Leukemia (CMML)
Interventions
DRUG

Cyclophosphamide

-Cyclophosphamide 50 mg/kg/day i.v. daily on days 3 and 4 (for 2 days)

Trial Locations (1)

05505

Asan Medical Center, University of Ulsan College of Medicine, Seoul

Sponsors
All Listed Sponsors
lead

Asan Medical Center

OTHER